4cnc
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Crystal structure of human 5T4 (Wnt-activated inhibitory factor 1, Trophoblast glycoprotein)== | |
- | + | <StructureSection load='4cnc' size='340' side='right' caption='[[4cnc]], [[Resolution|resolution]] 1.77Å' scene=''> | |
- | + | == Structural highlights == | |
+ | <table><tr><td colspan='2'>[[4cnc]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CNC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CNC FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4cnm|4cnm]]</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cnc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cnc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4cnc RCSB], [http://www.ebi.ac.uk/pdbsum/4cnc PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The tumor antigen 5T4/WAIF1 (Wnt-activated inhibitory factor 1; also known as Trophoblast glycoprotein TPBG) is a cell surface protein targeted in multiple cancer immunotherapy clinical trials. Recently, it has been shown that 5T4/WAIF1 inhibits Wnt/beta-catenin signaling, a signaling system central to many developmental and pathological processes. Wnt/beta-catenin signaling is controlled by multiple inhibitors and activators. Here, we report crystal structures for the extracellular domain of 5T4/WAIF1 at 1.8 A resolution. They reveal a highly glycosylated, rigid core, comprising eight leucine-rich repeats (LRRs), which serves as a platform to present evolutionarily conserved surface residues in the N-terminal LRR1. Structural and cell-based analyses, coupled with previously reported in vivo data, suggest that Tyr325 plus the LRR1 surface centered on a second exposed aromatic residue, Phe97, are essential for inhibition of Wnt/beta-catenin signaling. These results provide a structural basis for the development of 5T4/WAIF1-targeted therapies that preserve or block 5T4/WAIF1-mediated inhibition of Wnt/beta-catenin signaling. | ||
- | + | Structural Insights into the Inhibition of Wnt Signaling by Cancer Antigen 5T4/Wnt-Activated Inhibitory Factor 1.,Zhao Y, Malinauskas T, Harlos K, Jones EY Structure. 2014 Feb 25. pii: S0969-2126(14)00037-9. doi:, 10.1016/j.str.2014.01.009. PMID:24582434<ref>PMID:24582434</ref> | |
- | + | ||
- | == | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
- | + | </div> | |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
- | [[Category: Harlos, K | + | [[Category: Harlos, K]] |
- | [[Category: Jones, E Y | + | [[Category: Jones, E Y]] |
- | [[Category: Malinauskas, T | + | [[Category: Malinauskas, T]] |
- | [[Category: Zhao, Y | + | [[Category: Zhao, Y]] |
[[Category: Cancer]] | [[Category: Cancer]] | ||
[[Category: Cell adhesion]] | [[Category: Cell adhesion]] |
Revision as of 12:31, 4 January 2015
Crystal structure of human 5T4 (Wnt-activated inhibitory factor 1, Trophoblast glycoprotein)
|
Categories: Human | Harlos, K | Jones, E Y | Malinauskas, T | Zhao, Y | Cancer | Cell adhesion | Leucine-rich repeat | Signaling | Tpbg | Trovax | Waif1 | Wnt/beta-catenin signaling pathway